This bill mandates that healthcare providers enrolled in NJ FamilyCare, who are licensed to prescribe psychotropic drugs, must provide specific information and obtain consent from the parent or guardian of a child before prescribing such medications. The information to be shared includes the FDA-approved Medication Guide for the prescribed drug, details on evidence-based alternatives for treating the child's diagnosis, and guidance on accessing the FDA's Adverse Event Reporting System and MedWatch Online Voluntary Reporting Form. Additionally, the provider must secure a signed consent form from the parent or guardian, confirming their understanding of the drug's potential risks, awareness of alternatives, and knowledge of reporting tools for adverse effects.

The bill defines a "child" as any individual aged 18 years or younger enrolled in NJ FamilyCare, which encompasses both Medicaid and the Children's Health Insurance Program. It also outlines the responsibilities of the Commissioner of Human Services to apply for necessary state plan amendments or waivers to implement the bill and secure federal funding. Furthermore, the Commissioner is tasked with adopting rules and regulations to facilitate the bill's provisions, which will take effect three months after enactment, although anticipatory actions may be taken beforehand for implementation.